Camurus' NDA resubmission for CAM2029 in acromegaly accepted for review by the US FDA

NDA FilingCAM2029Positive

AI Analysis

Summary

Camurus announced that the FDA has accepted for review its NDA resubmission for CAM2029 (octreotide) for acromegaly treatment, with a PDUFA target action date of December 18, 2026.

Outcome Details

NDA resubmission accepted for review

Importance:7/10

Sentiment:

0.70

NDA resubmissionFDA acceptanceacromegalyoctreotidePDUFA date

Related Companies

$CAMX

Read the original article

Published by PR Newswire Pharma on July 17, 2026 5:25 AM

Read Original